{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:45:26Z","timestamp":1793187926209,"version":"4.5.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Despite recent advances, there is an urgent need for agents targeting HER2-expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a dendritic cell (DC) vaccine targeting HER2 in patients with metastatic cancer or bladder cancer at high risk of relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Part 1 of the study enrolled patients with HER2-expressing metastatic cancer that had progressed after at least standard treatment and patients who underwent definitive treatment for invasive bladder cancer with no evidence of disease at the time of enrollment. Part 2 enrolled patients with HER2-expressing metastatic cancer who had progressed after anti-HER2 therapy. The DC vaccines were prepared from autologous monocytes and transduced with an adenoviral vector expressing the extracellular and transmembrane domains of HER2 (AdHER2). A total of five doses were planned, and adverse events were recorded in patients who received at least one dose. Objective response was evaluated by unidimensional immune-related response criteria every 8 weeks in patients who received at least two doses. Humoral and cellular immunogenicity were assessed in patients who received more than three doses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 33 patients were enrolled at four dose levels (5 \u00d7 10<jats:sup>6<\/jats:sup>, 10 \u00d7 10<jats:sup>6<\/jats:sup>, 20 \u00d7 10<jats:sup>6<\/jats:sup>, and 40 \u00d7 10<jats:sup>6<\/jats:sup>DCs). Median follow-up duration was 36 weeks (4\u2013124); 10 patients completed five doses. The main reason for going off-study was disease progression. The main adverse events attributable to the vaccine were injection-site reactions. No cardiac toxicity was noted. Seven of 21 evaluable patients (33.3%) demonstrated clinical benefit (1 complete response, 1 partial response, and 5 stable disease). After \u22653 doses, an antibody response was detected in 3 of 13 patients (23.1%), including patients with complete and partial responses. Lymphocytes from 10 of 11 patients (90.9%) showed induction of anti-HER2 responses measured by the production of at least one of interferon-gamma, granzyme B, or tumor necrosis factor-alpha, and there were multifunctional responses in 8 of 11 patients (72.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The AdHER2 DC vaccine showed evidence of immunogenicity and preliminary clinical benefit in patients with HER2-expressing cancers, along with an excellent safety profile. It shows promise for further clinical applications, especially in combination regimens.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.789078","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T06:02:17Z","timestamp":1639634537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy"],"prefix":"10.3389","volume":"11","author":[{"given":"Hoyoung M.","family":"Maeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittni N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Inglefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Dunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Zen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Terabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee C.","family":"England","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Roberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana D.","family":"Pack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku M.","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic G.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Panch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Stroncek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren V.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Berzofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M300477200","article-title":"Quantitative Analysis of HER2-Mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis: Distribution of Homo- and Heterodimers Depends on Relative HER2 Levels","volume":"278","author":"Hendriks","year":"2003","journal-title":"J Biol Chem"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210477","article-title":"The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1962","article-title":"EGF\u2013ERBB Signalling: Towards the Systems Level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000368555","article-title":"Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer","volume":"88","author":"Park","year":"2015","journal-title":"Oncology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e98528","DOI":"10.1371\/journal.pone.0098528","article-title":"HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship Between HER2 Gene Amplification and Expression","volume":"9","author":"Seo","year":"2014","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106","article-title":"Human Breast Cancer: Correlation of Relapse and Survival With Amplification of the HER-2\/Neu Oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0430","article-title":"HER2 Amplification in Tumors Activates PI3K\/Akt Signaling Independent of HER3","volume":"78","author":"Ruiz-Saenz","year":"2018","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.74","article-title":"Signaling Cross-Talk in the Resistance to HER Family Receptor Targeted Therapy","volume":"33","author":"Yamaguchi","year":"2014","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity Profile of Trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf"},{"key":"B11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-012-2103-8","article-title":"Mechanisms of Cardiotoxicity Associated With ErbB2 Inhibitors","volume":"134","author":"Fedele","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61121-x","article-title":"Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.5966","article-title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2\/Neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.7.4228","article-title":"Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection Against Autochthonous Mammary Carcinomas","volume":"174","author":"Park","year":"2005","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3442","article-title":"Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated Neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice","volume":"64","author":"Sakai","year":"2004","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5688","article-title":"Therapy of Advanced Established Murine Breast Cancer With a Recombinant Adenoviral ErbB-2\/Neu Vaccine","volume":"68","author":"Park","year":"2008","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(02)00541-8","article-title":"Immunostimulating Reconstituted Influenza Virosomes","volume":"21","author":"Zurbriggen","year":"2003","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301488","article-title":"Efficient Infection of Primitive Hematopoietic Stem Cells by Modified Adenovirus","volume":"8","author":"Yotnda","year":"2001","journal-title":"Gene Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-Based Treatment of HER2-Positive Breast Cancer: An Antibody-Dependent Cellular Cytotoxicity Mechanism","volume":"94","author":"Arnould","year":"2006","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of Action and Use in Clinical Practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.03.001","article-title":"Plasma From Some Cancer Patients Inhibits Adenoviral Ad5f35 Vector Transduction of Dendritic Cells","volume":"20","author":"Jin","year":"2018","journal-title":"Cytotherapy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-325-7_14","article-title":"Statistical Analysis of ELISPOT Assays","volume":"792","author":"Dittrich","year":"2012","journal-title":"Methods Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2009.01.003","article-title":"Discovery of Epitopes for Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) With Antibodies","volume":"3","author":"Rockberg","year":"2009","journal-title":"Mol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","article-title":"Resistance Mechanisms to Anti-HER2 Therapies in HER2-Positive Breast Cancer: Current Knowledge, New Research Directions and Therapeutic Perspectives","volume":"139","author":"Vernieri","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.04.018","article-title":"Interleukin-2 Activity can be Fine Tuned With Engineered Receptor Signaling Clamps","volume":"42","author":"Mitra","year":"2015","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-1038","article-title":"Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2","volume":"19","author":"Rexer","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2309","article-title":"Combating Trastuzumab Resistance by Targeting SRC, a Common Node Downstream of Multiple Resistance Pathways","volume":"17","author":"Zhang","year":"2011","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-Cell-Based Therapeutic Cancer Vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0209-129","article-title":"The Cancer Vaccine Roller Coaster","volume":"27","author":"Goldman","year":"2009","journal-title":"Nat Biotechnol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing Erbb2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1158\/0008-5472.Can-07-5008","article-title":"Loss of CTL Function Among High-Avidity Tumor-Specific CD8+ T Cells Following Tumor Infiltration","volume":"68","author":"Janicki","year":"2008","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300803","article-title":"Rapid Deletion and Inactivation of CTLs Upon Recognition of a Number of Target Cells Over a Critical Threshold","volume":"191","author":"Prato","year":"2013","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","article-title":"Tumor Immunology and Tumor Evolution: Intertwined Histories","volume":"52","author":"Galon","year":"2020","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune Escape Mechanisms as a Guide for Cancer Immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05173-4","article-title":"Loss of HER2 After HER2-Targeted Treatment","volume":"175","author":"Ignatov","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30408","article-title":"HER2 Loss in HER2-Positive Gastric or Gastroesophageal Cancer After Trastuzumab Therapy: Implication for Further Clinical Research","volume":"139","author":"Pietrantonio","year":"2016","journal-title":"Int J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8346930","article-title":"Could Increased Expression of Hsp27, an \u201cAnti-Inflammatory\u201d Chaperone, Contribute to the Monocyte-Derived Dendritic Cell Bias Towards Tolerance Induction in Breast Cancer Patients","volume":"2019","author":"de Azevedo-Santos","year":"2019","journal-title":"Mediators Inflammation"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0442","article-title":"Tumor Antigen Escape From CAR T-Cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.445","article-title":"Neratinib Resistance and Cross-Resistance to Other HER2-Targeted Drugs Due to Increased Activity of Metabolism Enzyme Cytochrome P4503a4","volume":"116","author":"Breslin","year":"2017","journal-title":"Br J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7150\/jca.5482","article-title":"Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories","volume":"4","author":"Man","year":"2013","journal-title":"J Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1408749","DOI":"10.1080\/2162402x.2017.1408749","article-title":"Virus-Like Particle Display of HER2 Induces Potent Anti-Cancer Responses","volume":"7","author":"Palladini","year":"2018","journal-title":"Oncoimmunology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13058-018-1023-x","article-title":"Polyfunctional Anti-Human Epidermal Growth Factor Receptor 3 (Anti-HER3) Antibodies Induced by HER3 Vaccines Have Multiple Mechanisms of Antitumor Activity Against Therapy Resistant and Triple Negative Breast Cancers","volume":"20","author":"Osada","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1807465116","article-title":"Breaking Tolerance With Engineered Class I Antigen-Presenting Molecules","volume":"116","author":"Parks","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-17-0112","article-title":"Human Tumor Antigens Yesterday, Today, and Tomorrow","volume":"5","author":"Finn","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-08-2634","article-title":"Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer","volume":"68","author":"Cheung","year":"2008","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0960-8","article-title":"Immunologic Biomarkers as Correlates of Clinical Response to Cancer Immunotherapy","volume":"60","author":"Disis","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/2326-6066.Cir-19-0251","article-title":"Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity Through Antigen Spreading","volume":"8","author":"Xin","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02488","article-title":"HER2-Low Breast Cancer: Pathological and Clinical Landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"B57","first-page":"16","article-title":"Existent T-Cell and Antibody Immunity to HER-2\/Neu Protein in Patients With Breast Cancer","volume":"54","author":"Disis","year":"1994","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0331-0","article-title":"Coordinated Responses to Individual Tumor Antigens by IgG Antibody and CD8+ T Cells Following Cancer Vaccination","volume":"6","author":"Hulett","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1521812113","article-title":"Immunoproteasome Deficiency Is a Feature of Non-Small Cell Lung Cancer With a Mesenchymal Phenotype and Is Associated With a Poor Outcome","volume":"113","author":"Tripathi","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1996.0140","article-title":"Dendritic Cells in Antitumor Immune Responses. II. Dendritic Cells Grown From Bone Marrow Precursors, But Not Mature DC From Tumor-Bearing Mice, Are Effective Antigen Carriers in the Therapy of Established Tumors","volume":"170","author":"Gabrilovich","year":"1996","journal-title":"Cell Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.789078\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T17:57:23Z","timestamp":1674064643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.789078\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":60,"alternative-id":["10.3389\/fonc.2021.789078"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.789078","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]},"article-number":"789078"}}